All articles tagged with #oral medication
A clinical trial shows that an oral form of semaglutide, a drug used for weight loss and diabetes management, is effective in significantly reducing body weight, offering a less invasive alternative to injections. The study involved 205 participants and found an average weight loss of 13.6%, with manageable side effects, paving the way for potential regulatory approval of oral Ozempic.
A clinical trial shows that an oral form of Wegovy is as effective as the injectable version in promoting weight loss, with patients losing around 16.6% of their body weight over 64 weeks, fueling optimism for expanding weight-loss treatments. Both Novo Nordisk and Eli Lilly are racing to bring their oral obesity drugs to market, with promising trial results and plans for FDA approval, despite side effects and adherence challenges.
A new oral GLP-1 agonist, orforglipron, has shown promising results in a large trial, helping obese patients lose up to 11% of their body weight over 72 weeks, offering a potentially more accessible alternative to injectable treatments, with significant improvements in cardiometabolic health markers.
Eli Lilly's investigational oral daily nonpeptide GLP-1 agonist, Orforglipron, appears comparable with other injectable and oral agents in the class for treating obesity and type 2 diabetes, according to two new phase 2 studies. Orforglipron is a small molecule that isn't a peptide, so it isn't degraded in the gastrointestinal tract, making it more convenient for patients to take. The drug showed promising results in reducing body weight and A1c levels in patients with obesity and type 2 diabetes, respectively, and could potentially improve access to care for people with obesity who don't have the means to afford effective treatments.
Researchers at the University of Pennsylvania have developed a way to harvest insulin grown in lettuce, which can be taken orally and doesn't require painful injections. The plant-based insulin is cheaper, easier to distribute, and contains the missing C-peptide found in natural insulin, making it a better substitute for the real kind. The insulin is protected by the tough plant cell walls, allowing it to travel to the gut and eventually reach the liver. The next step is to trial the plant-based insulin in dogs and then people, potentially making insulin more affordable and accessible for the half a billion people with diabetes worldwide.